Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722137 · ClinicalTrials.gov registry record · Phase 3
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 487
- Enrollment target
NCT00722137 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 487 participants.
The verdict
NCT00722137, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 487 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.
Interventions
- DRUG Rituximab 375 mg/m^2
- DRUG Cyclophosphamide 750 mg/m^2
- DRUG Doxorubicin 50 mg/m^2
- DRUG VELCADE 1.3 mg/m^2
- DRUG Prednisone 100 mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2008-05-01 |
| Est. Completion | 2017-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722137
The ClinicalTrials.gov registry entry for NCT00722137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 487 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab 375 mg/m^2 is the first listed.
NCT00722137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722137 about?
NCT00722137 is a clinical study titled "Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma". This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.
What is the current status of trial NCT00722137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 487 participants. The study started on 2008-05-01. Estimated completion is 2017-06-17.
What interventions are being tested in trial NCT00722137?
The interventions under investigation include: Rituximab 375 mg/m^2 (DRUG), Cyclophosphamide 750 mg/m^2 (DRUG), Doxorubicin 50 mg/m^2 (DRUG), VELCADE 1.3 mg/m^2 (DRUG), Prednisone 100 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT00722137?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.